AR102539A1 - Triazolo[4,5-d]pirimidinas - Google Patents
Triazolo[4,5-d]pirimidinasInfo
- Publication number
- AR102539A1 AR102539A1 ARP150103585A ARP150103585A AR102539A1 AR 102539 A1 AR102539 A1 AR 102539A1 AR P150103585 A ARP150103585 A AR P150103585A AR P150103585 A ARP150103585 A AR P150103585A AR 102539 A1 AR102539 A1 AR 102539A1
- Authority
- AR
- Argentina
- Prior art keywords
- halopyridinyl
- halophenyl
- haloalkyl
- phenyl
- carbon atom
- Prior art date
Links
- -1 alkyloxazolyl Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 150000001721 carbon Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000005059 halophenyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000005036 alkoxyphenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000005037 alkyl phenyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000006456 halo alkyl cycloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000003566 oxetanyl group Chemical group 0.000 abstract 1
- 125000005475 oxolanyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
Abstract
Reivindicación 1: Compuesto de fórmula (1) en la que: n es 0, 1 ó 2; R¹ es fenilo, halofenilo, aquilsulfonilfenilo, alquiltetrazolilo, alquiloxadiazolilo, halohidroxialquilo, oxolanilo, oxetanilo, haloalquilo, halopiridinilo o alquiloxetanilo; R² es hidrógeno, hidroxilo, halógeno o haloalquilo, y R³ y R⁴ se seleccionan independientemente de entre alquilo, o R³ y R⁴, conjuntamente con el átomo de carbono al que se encuentran unidos, forman cicloalquilo, tietanilo, haloalquilcicloalquilo u oxotietanilo, o R² se encuentra ausente, y R³ y R⁴, conjuntamente con el átomo de carbono al que se encuentran unidos, forman alquilfenilo, halofenilo, alcoxifenilo, halopiridinilo, alquilpiridinilo, alquilpirazolilo, fenilo, alquiloxazolilo, pirazolilo, imidazolilo, benciltriazolilo o cicloalquenilo; o una sal o éster farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192245 | 2014-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102539A1 true AR102539A1 (es) | 2017-03-08 |
Family
ID=51945710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103585A AR102539A1 (es) | 2014-11-07 | 2015-11-05 | Triazolo[4,5-d]pirimidinas |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10183946B2 (es) |
| EP (1) | EP3215506B1 (es) |
| JP (1) | JP6669743B2 (es) |
| KR (1) | KR20170078781A (es) |
| CN (1) | CN107074864B (es) |
| AR (1) | AR102539A1 (es) |
| AU (1) | AU2015341811A1 (es) |
| BR (1) | BR112017009629A2 (es) |
| CA (1) | CA2960794A1 (es) |
| CL (1) | CL2017001100A1 (es) |
| CO (1) | CO2017003004A2 (es) |
| EA (1) | EA031735B1 (es) |
| IL (1) | IL250983A0 (es) |
| MX (1) | MX2017005857A (es) |
| PE (1) | PE20170683A1 (es) |
| PH (1) | PH12017500839A1 (es) |
| SG (1) | SG11201703416WA (es) |
| TW (1) | TW201625631A (es) |
| WO (1) | WO2016071375A1 (es) |
| ZA (1) | ZA201701814B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA031735B1 (ru) | 2014-11-07 | 2019-02-28 | Ф. Хоффманн-Ля Рош Аг | ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2 |
| WO2017220544A1 (en) | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives |
| WO2017220516A1 (en) | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives |
| WO2018015088A1 (en) | 2016-06-23 | 2018-01-25 | F. Hoffmann-La Roche Ag | Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives |
| KR20230062680A (ko) | 2016-06-23 | 2023-05-09 | 에프. 호프만-라 로슈 아게 | 2형 칸나비노이드 수용체에 대한 친화성을 갖는 [1,2,3]트라이아졸로[4,5-d]피리미딘 유도체 |
| KR20230093251A (ko) | 2020-09-10 | 2023-06-27 | 프리시릭스 엔.브이. | Fap에 대한 항체 단편 |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
| AU2023283632A1 (en) * | 2022-06-07 | 2024-11-07 | F. Hoffmann-La Roche Ag | A process for preparing 1-[5-tert-butyl-3-[(1-methyltetrazol-5 -yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2368881A1 (en) * | 2005-01-10 | 2011-09-28 | University of Connecticut | Heteropyrazole analogs acting on cannabinoid receptors |
| EA200702377A1 (ru) * | 2005-04-29 | 2008-02-28 | Янссен Фармацевтика Н.В. | Производные бензотриазола в качестве антагонистов каннабиноидного рецептора |
| CN101631789A (zh) | 2006-12-14 | 2010-01-20 | 百时美施贵宝公司 | 作为大麻素受体调节剂的氮杂双环杂环 |
| US7655685B2 (en) | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| AR080711A1 (es) * | 2010-03-31 | 2012-05-02 | Lilly Co Eli | Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor |
| UA111640C2 (uk) * | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 |
| US9067943B2 (en) | 2011-11-25 | 2015-06-30 | Hoffmann-La Roche Inc. | [1,2,3]triazolo[4,5-D]pyrimidine derivatives |
| RS57461B1 (sr) * | 2013-05-02 | 2018-09-28 | Hoffmann La Roche | Derivati purina kao agonisti cb2 receptora |
| AU2014261546B2 (en) * | 2013-05-02 | 2018-01-18 | F. Hoffmann-La Roche Ag | Pyrrolo[2,3-d]pyrimidine derivatives as CB2 receptor agonists |
| MX391724B (es) | 2013-09-06 | 2025-03-21 | Hoffmann La Roche | Nuevos derivados de triazolo[4,5-d]pirimidina. |
| EA031735B1 (ru) | 2014-11-07 | 2019-02-28 | Ф. Хоффманн-Ля Рош Аг | ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2 |
-
2015
- 2015-11-04 EA EA201790939A patent/EA031735B1/ru not_active IP Right Cessation
- 2015-11-04 AU AU2015341811A patent/AU2015341811A1/en not_active Abandoned
- 2015-11-04 BR BR112017009629A patent/BR112017009629A2/pt not_active Application Discontinuation
- 2015-11-04 CA CA2960794A patent/CA2960794A1/en not_active Abandoned
- 2015-11-04 EP EP15788083.2A patent/EP3215506B1/en not_active Not-in-force
- 2015-11-04 PE PE2017000489A patent/PE20170683A1/es unknown
- 2015-11-04 SG SG11201703416WA patent/SG11201703416WA/en unknown
- 2015-11-04 WO PCT/EP2015/075654 patent/WO2016071375A1/en not_active Ceased
- 2015-11-04 KR KR1020177014684A patent/KR20170078781A/ko not_active Withdrawn
- 2015-11-04 CN CN201580057112.3A patent/CN107074864B/zh not_active Expired - Fee Related
- 2015-11-04 JP JP2017524001A patent/JP6669743B2/ja not_active Expired - Fee Related
- 2015-11-04 MX MX2017005857A patent/MX2017005857A/es unknown
- 2015-11-05 AR ARP150103585A patent/AR102539A1/es unknown
- 2015-11-05 TW TW104136550A patent/TW201625631A/zh unknown
-
2017
- 2017-03-07 IL IL250983A patent/IL250983A0/en unknown
- 2017-03-14 ZA ZA2017/01814A patent/ZA201701814B/en unknown
- 2017-03-28 CO CONC2017/0003004A patent/CO2017003004A2/es unknown
- 2017-04-04 US US15/478,435 patent/US10183946B2/en not_active Expired - Fee Related
- 2017-05-03 CL CL2017001100A patent/CL2017001100A1/es unknown
- 2017-05-05 PH PH12017500839A patent/PH12017500839A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107074864A (zh) | 2017-08-18 |
| JP6669743B2 (ja) | 2020-03-18 |
| EA201790939A1 (ru) | 2017-08-31 |
| MX2017005857A (es) | 2017-06-26 |
| US10183946B2 (en) | 2019-01-22 |
| PE20170683A1 (es) | 2017-05-22 |
| PH12017500839A1 (en) | 2017-10-30 |
| AU2015341811A1 (en) | 2017-03-30 |
| KR20170078781A (ko) | 2017-07-07 |
| EP3215506A1 (en) | 2017-09-13 |
| CO2017003004A2 (es) | 2017-07-19 |
| TW201625631A (zh) | 2016-07-16 |
| WO2016071375A1 (en) | 2016-05-12 |
| EA031735B1 (ru) | 2019-02-28 |
| SG11201703416WA (en) | 2017-05-30 |
| CL2017001100A1 (es) | 2018-01-05 |
| EP3215506B1 (en) | 2019-01-02 |
| BR112017009629A2 (pt) | 2017-12-19 |
| IL250983A0 (en) | 2017-04-30 |
| ZA201701814B (en) | 2018-05-30 |
| CA2960794A1 (en) | 2016-05-12 |
| US20170204103A1 (en) | 2017-07-20 |
| JP2017533918A (ja) | 2017-11-16 |
| CN107074864B (zh) | 2019-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102539A1 (es) | Triazolo[4,5-d]pirimidinas | |
| AR095721A1 (es) | Derivados de piridina | |
| AR101558A1 (es) | Difluoropirrolidinas como moduladores del receptor de orexina | |
| AR098912A1 (es) | Inhibidores de syk | |
| AR094712A1 (es) | Modificador de sabor dulce | |
| AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
| MX2017015277A (es) | Derivado de pirido[3,4-d]pirimidina y sal farmaceuticamente aceptable de este. | |
| AR094978A1 (es) | Derivados de pirazol agonistas de receptores canabinoides | |
| JO3392B1 (ar) | مركبات عطرية حلقية غير متجانسة كمركبات مضادة للالتهاب | |
| MY180083A (en) | Tetrahydropyrrolothiazine compounds | |
| CU20170057A7 (es) | Derivados de feniltriazol sustituido con hidroxialquilo | |
| MX2015012629A (es) | Compuestos de imidazo piridina. | |
| EA201591503A1 (ru) | Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина | |
| UY35333A (es) | Compuestos de azabencimidazol | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR094214A1 (es) | Inhibidores de la quinasa que regula la señal de la apoptosis | |
| MX2016006336A (es) | Compuestos pirazolopirimidina. | |
| AR096153A1 (es) | Derivados de pirrolo[2,3-d]pirimidina | |
| MX381970B (es) | Derivado de sulfonamida y composición farmacéutica que contiene el mismo. | |
| AR095097A1 (es) | Compuestos de fenoxietoxi | |
| EA201591815A1 (ru) | Бицикло [2.2.2] кислоты - модуляторы gpr120 | |
| MY181739A (en) | An article of furniture | |
| AR096152A1 (es) | Derivados de purina | |
| AR101359A1 (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo | |
| MX2015015562A (es) | Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |